SAN DIEGO, Nov. 19, 2013 /PRNewswire/ -- Organovo
Holdings, Inc. (NYSE MKT: ONVO) (" Organovo "), a three-dimensional
biology company focused on delivering breakthrough 3D bioprinting
technology, has been invited to present at the 25th Annual Piper
Jaffray Healthcare Conference, which will be held in New York December 3-4,
2013.
Organovo's Chairman and Chief Executive Officer, Keith Murphy, will be presenting on Wednesday, December 4, at 3:30pm ET Mr.
Murphy will also be participating in a panel discussion on 3D
Printing on Tuesday, December 3, at
2:00pm ET.
The goal of Piper Jaffray's 25th
Annual Healthcare Conference is to bring together key industry
executives, investors and Piper professionals to provide multiple
perspectives, investigate critical trends and identify the leaders
in the markets that are driving our economy. The conference
will be held at The New York Palace – New
York.
About Organovo Holdings, Inc.
Organovo designs and creates functional, three-dimensional human
tissues for medical research and therapeutic applications. The
Company is collaborating with pharmaceutical and academic partners
to develop human biological disease models in three dimensions.
These 3D human tissues have the potential to accelerate the drug
discovery process, enabling treatments to be developed faster and
at lower cost. In addition to numerous scientific publications, the
Company's technology has been featured in The Wall Street Journal,
Time Magazine, The Economist, and numerous others. Organovo is
changing the shape of medical research and practice. Learn more at
www.organovo.com.
Safe Harbor Statement
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995. Any forward-looking statements contained herein are
based on current expectations, but are subject to a number of risks
and uncertainties. The factors that could cause actual future
results to differ materially from current expectations include, but
are not limited to, risks and uncertainties relating to the
Company's ability to develop, market and sell products based on its
technology; the expected benefits and efficacy of the Company's
products and technology; and the Company's business, research,
product development, regulatory approval, marketing and
distribution plans and strategies. These and other factors are
identified and described in more detail in our filings with the
SEC, including our report on Form 10-Q filed November 8, 2013, the prospectus supplement filed
with the SEC on August 2, 2013 and
the transition report on Form 10-KT filed with the SEC on
May 24, 2013 and our other filings
with the Securities and Exchange Commission. You should not place
undue reliance on these forward-looking statements, which speak
only as of the date that they were made. These cautionary
statements should be considered with any written or oral
forward-looking statements that we may issue in the future. Except
as required by applicable law, including the securities laws of
the United States, we do not
intend to update any of the forward-looking statements to conform
these statements to reflect actual results, later events or
circumstances or to reflect the occurrence of unanticipated
events.
SOURCE Organovo Holdings, Inc.